Latest On Takeda Pharmaceutical Company Limited (TKPHF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2021-03-30 06:01 EST | Dividend | A dividend of $90 has been announced on May 13, 2020. It will be paid Nov 30, -0001 with an ex-dividend date of Mar 30, 2021. | Neutral |  |
| 2021-02-06 01:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 22:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-03 01:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-03 06:04 EST | Earnings Estimate | An EPS average of $2.20 is estimated for the 2022 year. | Buy | |
| 2020-08-03 06:04 EST | Earnings Estimate | An EPS average of $0.53 is estimated for the 2021 year. | Buy | |
| 2020-08-02 02:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:37 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:21 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:20 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:17 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 07:51 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 06:53 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-16 02:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 21:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-15 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 14:19 EST | News | Takeda Pharmaceutical reports FY results | N/A | |
| 2020-05-14 14:19 EST | News | Takeda Pharmaceutical Company Limited 2019 Q4 - Results - Earnings Call Presentation | N/A | |
| 2020-05-14 14:18 EST | News | Takeda Pharmaceutical Company Limited (TKPHF) on Q4 2019 Results - Earnings Call Transcript | N/A | |
| 2020-05-06 07:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 18:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-20 05:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-14 11:17 EST | News | Takeda clears FDA hurdle on Alunbrig | N/A | |
| 2020-04-14 11:15 EST | News | Takeda gets positive CHMP opinion for subcutaneous vedolizumab | N/A | |
| 2020-04-14 11:15 EST | News | Takeda sues Sun Pharma to halt copies of cancer drug | N/A | |
| 2020-04-14 10:48 EST | News | Evotec inks deal with and Takeda for gene therapy programs | N/A | |
| 2020-04-14 10:48 EST | News | Takeda’s Alunbrig approved as a first-line treatment for ALK+ NSCLC in Europe | N/A | |
| 2020-04-07 06:03 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-03 22:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-30 06:03 EST | Dividend | A dividend of $90 has been announced on May 14, 2019. It will be paid Jan 1, 1970 with an ex-dividend date of Mar 30, 2020. | Neutral | |
| 2020-03-25 22:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-28 05:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 00:42 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 00:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-13 01:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-08 00:48 EST | Financials | Company financials have been released. | Neutral | |
About Takeda Pharmaceutical Company Limited (TKPHF):
Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with TESARO, Inc., Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Rani Therapeutics LLC, Novimmune S.A., AB Biosciences Inc., Sosei Group Corporation, and LogicBio Therapeutics, Inc.; strategic collaboration with Prometheus Biosciences, Inc; a license and research agreement with The University of Texas MD Anderson Cancer Center; a research collaboration agreements with Enzyre BV and Cerevance; a collaboration agreement with Artisan Bio, Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a corporate strategic research alliance with Egle Therapeutics SAS; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; and strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
General
- Name Takeda Pharmaceutical Company Limited
- Symbol TKPHF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 47,495
- Fiscal Year EndMarch
- Web URLhttp://www.takeda.com
Valuation
- Trailing PE 23.76
- Forward PE 10.56
- Price/Sales (Trailing 12 Mt.) 2.1
- Price/Book (Most Recent Quarter) 1.45
- Enterprise Value Revenue 0.03
- Enterprise Value EBITDA 0.11
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $1.20
- Next Year EPS Estimate $2.13
- Profit Margin 6%
- Return on Assets 1%
- Return on Equity 4%
- Earnings Per Share $1.62
- Revenue Per Share $0
- Gross Profit 2.2 trillion
- Quarterly Earnings Growth -2.6%
ESG Rating
Highlights
- Market Capitalization 60.67 billion
- PE Ratio 31.86
- PEG Ratio 0.14
- Book Value Per Share $25.10
Share Statistics
- Shares Outstanding 1.58 billion
- Shares Float 1.56 billion
- % Held by Insiders 10%
- % Held by Institutions 38.69%
Technicals
- Beta 1.11
- 52 Week High $39.1
- 52 Week Low $24.17
- 50 Day Moving Average 35.33
- 200 Day Moving Average 35.47
Dividends
- Forward Annual Dividend Rate $1.68
- Forward Annual Dividend Yield 4.3%
- Payout Ratio 154%
- Dividend Date 2010-06-28
- ExDividend Date 2021-03-30
- Dividend Per Share $1.64
- Dividend Yield 0%
Takeda Pharmaceutical Company Limited (TKPHF) Dividend Calendar:
TKPHF's last dividend payment was made to shareholders on June 28, 2010.
Takeda Pharmaceutical Company Limited pays out 154% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Takeda Pharmaceutical Company Limited (TKPHF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $836.75 billion | $0.56 | ||
| 2020-09-30 | 2020-12-31 | $N/A | $0.57 | ||
| 2020-06-30 | 2020-09-30 | $N/A | $0.02 | $7.96 | -99.69% |
| 2020-03-31 | 2020-06-30 | $771.7 billion | $0.49 | ||
| 2019-12-31 | 2020-03-31 | $7.91 billion | $0.01 | ||
| 2019-09-30 | 2019-12-31 | $7.5 billion | -$0.19 | ||
| 2019-06-30 | 2019-09-30 | $7.84 billion | $0.40 | ||
| 2019-03-31 | 2019-06-30 | $6.44 billion | $0.04 | ||
| 2018-12-31 | 2019-03-31 | $4.56 billion | -$0.18 | ||
| 2018-09-30 | 2018-12-31 | $3.78 billion | $0.44 | ||
| 2018-06-30 | 2018-09-30 | $4.06 billion | $0.54 | $75.90 | -99.29% |
| 2018-03-31 | 2018-06-30 | $3.79 billion | $0.90 | -$60.20 | 101.49% |
| 2017-12-31 | 2018-03-31 | $4.33 billion | -$0.65 | $29.40 | -102.21% |
| 2017-09-30 | 2017-12-31 | $3.84 billion | $0.77 | -$2.80 | 127.44% |
| 2017-06-30 | 2017-09-30 | $3.99 billion | $0.32 | $130.30 | -99.76% |
| 2017-03-31 | 2017-06-30 | $416.21 billion | $1.64 | ||
| 2016-12-31 | 2017-03-31 | $465.05 billion | -$0.58 | ||
| 2016-09-30 | 2016-12-31 | $416.8 billion | $0.45 | $16.70 | -97.3% |
| 2016-06-30 | 2016-09-30 | $434.01 billion | $0.31 | $107.95 | -99.71% |
| 2016-03-31 | 2016-06-30 | $414.12 billion | $1.23 | -$45.60 | 102.71% |
| 2015-12-31 | 2016-03-31 | -$0.38 | $28.10 | -101.36% | |
| 2015-09-30 | 2015-12-31 | $0.62 | |||
| 2015-06-30 | 2015-09-30 | $0.32 | |||
| 2015-03-31 | 2015-06-30 | $0.25 | |||
| 2014-12-31 | 2015-03-31 | -$2.39 | $44.05 | -105.43% | |
| 2014-09-30 | 2014-12-31 | $0.19 | $34.40 | -99.44% | |
| 2014-06-30 | 2014-09-30 | $0.32 | |||
| 2014-03-31 | 2014-06-30 | $0.42 | $6.00 | -93.03% | |
| 2013-12-31 | 2014-03-31 | -$0.05 | $0.40 | -113.35% | |
| 2013-09-30 | 2013-12-31 | $0.56 | |||
| 2013-06-30 | 2013-09-30 | $0.46 | |||
| 2013-03-31 | 2013-06-30 | $0.37 | |||
| 2012-12-31 | 2013-03-31 | -$0.10 | |||
| 2012-09-30 | 2012-12-31 | $0.28 | |||
| 2012-06-30 | 2012-09-30 | $0.52 | |||
| 2012-03-31 | 2012-06-30 | $1.39 | |||
| 2011-12-31 | 2012-03-31 | -$0.56 | |||
| 2011-09-30 | 2011-12-31 | $0.41 | |||
| 2011-06-30 | 2011-09-30 | $0.99 | |||
| 2011-03-31 | 2011-06-30 | $1.19 | |||
| 2010-12-31 | 2011-03-31 | $0.49 | |||
| 2010-09-30 | 2010-12-31 | $1.11 | |||
| 2010-06-30 | 2010-06-30 | $0.88 | |||
| 2008-09-30 | 2008-09-30 | $0.78 | |||
| 2008-06-30 | 2008-06-30 | $0.03 | |||
| 2008-03-31 | 2008-03-31 | $0.28 | |||
| 2007-06-30 | 2007-06-30 | $1.26 | |||
| 2007-03-31 | 2007-03-31 | $0.68 | |||
| 2006-12-31 | 2006-12-31 | $1.05 | |||
| 2006-09-30 | 2006-09-30 | $0.34 | |||
| 2006-06-30 | 2006-06-30 | $1.24 | |||
| 2006-03-31 | 2006-03-31 | $0.31 | |||
| 2005-12-31 | 2005-12-31 | $0.96 | |||
| 2005-09-30 | 2005-09-30 | $0.67 | |||
| 2005-06-30 | 2005-06-30 | $1.21 | |||
| 2005-03-31 | 2005-03-31 | $0.34 | |||
| 2004-12-31 | 2004-12-31 | $0.88 | |||
| 2004-09-30 | 2004-09-30 | $0.75 | |||
| 2004-06-30 | 2004-06-30 | $0.92 |
Takeda Pharmaceutical Company Limited (TKPHF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 117.57 billion | N/A | N/A | 139.31 billion | 1.13 billion |
| Income Before Tax | 109.8 billion | N/A | N/A | -116.76 billion | 769.3 million |
| Selling General Administrative | 222.64 billion | N/A | N/A | 253.06 billion | 2.26 billion |
| Gross Profit | 583.61 billion | N/A | N/A | 523.52 billion | 5.64 billion |
| Ebit | 312.22 billion | N/A | N/A | 70.02 billion | 1.59 billion |
| Operating Income | 143.14 billion | N/A | N/A | -62.14 billion | 1.59 billion |
| Income Tax Expense | N/A | -8.8 billion | 47.77 billion | N/A | 682.32 million |
| Total Revenue | 836.75 billion | N/A | N/A | 771.7 billion | 7.91 billion |
| Cost of Revenue | 253.14 billion | N/A | N/A | 248.18 billion | 2.27 billion |
| Total Other Income Expense Net | 922 million | N/A | N/A | -8.89 billion | -823.77 million |
| Net Income From Continuing Operations | 92.44 billion | N/A | N/A | 1.56 billion | 86.98 million |
| Net Income Applicable to Common Shares | N/A | 4.04 billion | 82.51 billion | N/A | 85.92 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | 36.25 billion | 35.28 million | 234.19 million |
| Change to Liabilities | -3.18 billion | -23.15 billion | N/A | 21.01 million | -103.45 million |
| Total Cash Flow from Investing Activities | 27.56 billion | 662 million | N/A | -686.21 million | 3.44 billion |
| Net Borrowings | -164.62 billion | -27.19 billion | N/A | 1.19 billion | -5.47 billion |
| Total Cash Flow from Financial Activities | N/A | N/A | -143.93 billion | -456.73 million | -5.87 billion |
| Change to Operating Activities | 12.94 billion | 2.18 billion | N/A | 225.7 million | 211.57 million |
| Change in Cash | N/A | N/A | 77.75 billion | 222.17 million | -464.73 million |
| Total Cash from Operating Activities | 246.15 billion | 145.86 billion | 185.44 billion | 1.32 billion | 2.04 billion |
| Depreciation | N/A | N/A | 145.73 billion | 883.32 million | 1.53 billion |
| Other Cash Flow from Investing Activities | -5.44 billion | 193 million | N/A | -1.47 million | 42.61 million |
| Change to Inventory | N/A | N/A | 44.75 billion | 200.32 million | 169.68 million |
| Change to Account Receivables | N/A | N/A | N/A | -137.91 million | -83.76 million |
| Other Cash Flow from Financing Activities | -52.19 billion | -30.33 billion | N/A | -421.52 million | -284.08 million |
| Change to Net Income | 61.74 billion | -27.05 billion | N/A | 40.19 million | -186.49 million |
| Capital Expenditures | N/A | N/A | 62.88 billion | 320.02 million | 233.38 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 7.65 trillion | N/A | N/A | 8.09 trillion | 75.08 billion |
| Total Stockholder Equity | 4.64 trillion | N/A | N/A | 4.72 trillion | 44.85 billion |
| Other Current Liabilities | 596 billion | 1.16 trillion | N/A | 682.28 billion | 11.19 billion |
| Total Assets | 12.29 trillion | N/A | N/A | 12.82 trillion | 119.97 billion |
| Common Stock | N/A | 1.67 trillion | 1.67 trillion | N/A | 15.36 billion |
| Other Current Assets | 115.7 billion | 425.67 billion | N/A | 114.2 billion | 2.56 billion |
| Retained Earnings | 1.31 trillion | 1.34 trillion | 1.33 trillion | 1.37 trillion | 12.69 billion |
| Other Liabilities | N/A | 930.56 billion | 991.16 billion | N/A | 9.29 billion |
| Other Assets | N/A | 378.66 billion | 408.85 billion | N/A | 2.17 billion |
| Cash | 617.64 billion | N/A | N/A | 637.61 billion | 5.23 billion |
| Total Current Liabilities | 1.8 trillion | 1.71 trillion | N/A | 2.18 trillion | 19.58 billion |
| Other Stockholder Equity | N/A | 47.89 billion | 87.81 billion | N/A | 2.2 billion |
| Property, Plant & Equipment | N/A | 1.37 trillion | 1.37 trillion | N/A | 13.52 billion |
| Total Current Assets | 2.62 trillion | 2.59 trillion | N/A | 2.47 trillion | 23.2 billion |
| Long Term Investments | 376.05 billion | N/A | N/A | 369.46 billion | 3.63 billion |
| Net Tangible Assets | N/A | -3.07 trillion | -3.34 trillion | N/A | -32.59 billion |
| Short Term Investments | 36.66 billion | N/A | N/A | 15.82 billion | 185.45 million |
| Long Term Debt | 4.47 trillion | N/A | N/A | 4.51 trillion | 42.44 billion |
| Inventory | 739.35 billion | 743.48 billion | N/A | 759.6 billion | 7.38 billion |
| Accounts Payable | 326.98 billion | 272.78 billion | N/A | 318.82 billion | 2.76 billion |
Takeda Pharmaceutical Company Limited (TKPHF) Chart:
Takeda Pharmaceutical Company Limited (TKPHF) News:
Below you will find a list of latest news for Takeda Pharmaceutical Company Limited (TKPHF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Takeda Pharmaceutical Company Limited (TKPHF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Takeda Pharmaceutical Company Limited (TKPHF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|